Identification of NR4A2 As a Transcriptional Activator of IL-8 Expression in Human Inflammatory Arthritis
Overview
Molecular Biology
Affiliations
Expression of the orphan nuclear receptor NR4A2 is controlled by pro-inflammatory mediators, suggesting that NR4A2 may contribute to pathological processes in the inflammatory lesion. This study identifies the chemoattractant protein, interleukin 8 (IL-8/CXCL8), as a molecular target of NR4A2 in human inflammatory arthritis and examines the mechanism through which NR4A2 modulates IL-8 expression. In TNF-alpha-activated human synoviocyte cells, enhanced expression of IL-8 mRNA and protein correspond to temporal changes in NR4A2 transcription and nuclear distribution. Ectopic expression of NR4A2 leads to robust changes in endogenous IL-8 mRNA levels and co-treatment with TNF-alpha results in significant (p<0.001) secretion of IL-8 protein. Transcriptional effects of NR4A2 on the human IL-8 promoter are enhanced in the presence of TNF-alpha, suggesting molecular crosstalk between TNF-alpha signalling and NR4A2. A dominant negative IkappaB kinase antagonizes the combined effects of NR4A2 and TNF-alpha on IL-8 promoter activity. Co-expression of NR4A2 and the p65 subunit of NF-kappaB enhances IL-8 transcription and functional studies indicate that transactivation occurs independently of NR4A2 binding to DNA or heterodimerization with additional nuclear receptors. The IL-8 minimal promoter region is sufficient to support NR4A2 and NF-kappaB/p65 co-operative activity and NR4A2 can interact with NF-kappaB/p65 on a 39bp sequence within this region. In patients treated with methotrexate for active inflammatory arthritis, a reduction in NR4A2 synovial tissue levels correlate significantly (n=10, r=0.73, p=0.002) with changes in IL-8 expression. Collectively, these data delineate an important role for NR4A2 in modulating IL-8 expression and reveal novel transcriptional responses to TNF-alpha in human inflammatory joint disease.
Identification of key hub genes in knee osteoarthritis through integrated bioinformatics analysis.
Xu L, Ma J, Zhou C, Shen Z, Zhu K, Wu X Sci Rep. 2024; 14(1):22437.
PMID: 39341952 PMC: 11439059. DOI: 10.1038/s41598-024-73188-z.
Phelan D, Reddan B, Shigemura M, Sznajder J, Crean D, Cummins E Int J Mol Sci. 2024; 25(5).
PMID: 38474099 PMC: 10931687. DOI: 10.3390/ijms25052852.
NR4A1-3 nuclear receptor activity and immune cell dysregulation in rheumatic diseases.
Murphy E, Crean D Front Med (Lausanne). 2022; 9:874182.
PMID: 35935773 PMC: 9354819. DOI: 10.3389/fmed.2022.874182.
Yao P, Parmar V, Choudhary M, Malek G Proc Natl Acad Sci U S A. 2022; 119(28):e2202256119.
PMID: 35867766 PMC: 9282432. DOI: 10.1073/pnas.2202256119.
Lilley C, Alarcon A, Ngo M, Araujo J, Marrero L, Mix K Front Pharmacol. 2022; 13:835697.
PMID: 35529439 PMC: 9067626. DOI: 10.3389/fphar.2022.835697.